HDL Diagnostics, Inc. (“HDL Dx”) is an early stage diagnostics company focused on cardiovascular disease (CVD). The company has filed a provisional patent application on its technology: tests to assess the functional status of high density lipoproteins (HDL). HDL, commonly called the “good cholesterol,” is a complex biological particle composed of multiple proteins and lipids that mediate several functions including inhibiting arterial inflammation and removing excess cholesterol. Recent peer-reviewed articles suggest that HDL dysfunction, which can occur in individuals who have “normal” cholesterol levels, leads to CVD. HDL Dx’s goal is to provide a new technology to comprehensively assess the multiple functions of HDL as a means of identifying individuals who are at increased risk of CVD.